ATE535535T1 - Methoden für die diagnose von demenz und anderen neurologischen erkrankungen - Google Patents
Methoden für die diagnose von demenz und anderen neurologischen erkrankungenInfo
- Publication number
- ATE535535T1 ATE535535T1 AT07710657T AT07710657T ATE535535T1 AT E535535 T1 ATE535535 T1 AT E535535T1 AT 07710657 T AT07710657 T AT 07710657T AT 07710657 T AT07710657 T AT 07710657T AT E535535 T1 ATE535535 T1 AT E535535T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- alzheimer
- disease dementia
- accurate mass
- methods
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000004896 high resolution mass spectrometry Methods 0.000 abstract 1
- 239000013074 reference sample Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N37/00—Details not covered by any other group of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/16—Phosphorus containing
- Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77729006P | 2006-02-28 | 2006-02-28 | |
| US80477906P | 2006-06-14 | 2006-06-14 | |
| US88888307P | 2007-02-08 | 2007-02-08 | |
| PCT/CA2007/000313 WO2007098585A1 (en) | 2006-02-28 | 2007-02-28 | Methods for the diagnosis of dementia and other neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535535T1 true ATE535535T1 (de) | 2011-12-15 |
Family
ID=38458611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07710657T ATE535535T1 (de) | 2006-02-28 | 2007-02-28 | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8304246B2 (de) |
| EP (3) | EP2322531A3 (de) |
| JP (3) | JP5496513B2 (de) |
| KR (1) | KR20080104350A (de) |
| AT (1) | ATE535535T1 (de) |
| AU (1) | AU2007219666A1 (de) |
| CA (2) | CA2640748C (de) |
| HK (1) | HK1208467A1 (de) |
| IL (1) | IL193426A0 (de) |
| NZ (1) | NZ570413A (de) |
| WO (1) | WO2007098585A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2620147B1 (de) | 2007-02-08 | 2020-06-03 | Med-Life Discoveries LP | Verbindungen zur Senkung des Cholesterins |
| CA2680748C (en) * | 2007-04-13 | 2012-08-28 | Phenomenome Discoveries Inc. | Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging |
| JP5306345B2 (ja) * | 2007-07-26 | 2013-10-02 | フェノメノーム ディスカバリーズ インク | 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法 |
| EP3358354B1 (de) | 2008-01-18 | 2020-07-15 | President and Fellows of Harvard College | Verfahren zur detektion von anzeichen einer krankheit oder eines leidens in körperflüssigkeiten |
| US9965035B2 (en) | 2008-05-13 | 2018-05-08 | Apple Inc. | Device, method, and graphical user interface for synchronizing two or more displays |
| US9121844B1 (en) * | 2008-09-09 | 2015-09-01 | Sociedad Europea de Analisis Diferencial de Movilidad | Method to analyze and classify persons and organisms based on odor patterns from released vapors |
| TWI475989B (zh) | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法 |
| EP3124980A1 (de) | 2009-10-01 | 2017-02-01 | Phenomenome Discoveries Inc. | Mass-spectrophotometrische methode zur diagnose pancreatischem krebs |
| US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
| MX382244B (es) | 2010-07-23 | 2025-03-13 | Harvard College | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales |
| CA2806293A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| SG10201505724SA (en) | 2010-07-23 | 2015-09-29 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| JP6025568B2 (ja) * | 2010-12-28 | 2016-11-16 | 株式会社藤野ブレインリサーチ | 認知症を血液サンプルで判定するための検査方法 |
| WO2013071412A1 (en) * | 2011-11-17 | 2013-05-23 | Phenomenome Discoveries Inc. | Methods for the synthesis of 13c labeled plasmalogen |
| WO2013119651A1 (en) * | 2012-02-08 | 2013-08-15 | Nestec Sa | Methods for diagnosing cognitive impairment |
| US20150031572A1 (en) * | 2012-02-15 | 2015-01-29 | Basf Se | Means and methods for assessing neuronal toxicity |
| CN104246781B (zh) * | 2012-03-29 | 2019-06-14 | 皇家飞利浦有限公司 | 用于改进神经科医师的关于阿尔茨海默氏病的工作流程的系统与方法 |
| CN104603289A (zh) | 2012-06-15 | 2015-05-06 | 哈里·斯泰利 | 检测疾病或病状的方法 |
| SG11201408383SA (en) | 2012-06-15 | 2015-01-29 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| EP4202441A3 (de) | 2013-03-09 | 2023-07-26 | Immunis.AI, Inc. | Genexpressionsprofil in makrophagen zur diagnose von krebs |
| WO2014197339A1 (en) | 2013-06-08 | 2014-12-11 | Apple Inc. | Device, method, and graphical user interface for synchronizing two or more displays |
| CN105723223B (zh) * | 2013-11-14 | 2019-04-09 | 雀巢产品技术援助有限公司 | 预测健康衰老的脂质生物标志物 |
| US20160235778A1 (en) * | 2014-03-13 | 2016-08-18 | Massachusetts Institute Of Technology | Compositions containing pufa, uridine and choline and methods of use thereof |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| US10006925B2 (en) | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
| GB201611596D0 (en) * | 2016-07-04 | 2016-08-17 | British American Tobacco Investments Ltd | Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories |
| WO2018157013A1 (en) * | 2017-02-24 | 2018-08-30 | Duke University | Compositions and methods related to sex-specific metabolic drivers in alzheimer's disease |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2019246239A1 (en) | 2018-06-19 | 2019-12-26 | Ellipsis Health, Inc. | Systems and methods for mental health assessment |
| US20190385711A1 (en) | 2018-06-19 | 2019-12-19 | Ellipsis Health, Inc. | Systems and methods for mental health assessment |
| SG11202100147VA (en) * | 2018-07-13 | 2021-02-25 | Pst Inc | Apparatus for estimating mental/neurological disease |
| CN113382683A (zh) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | 改善睡眠的系统和方法 |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| WO2022263927A2 (en) * | 2021-06-17 | 2022-12-22 | Phoska Biopharma Pte. Ltd. | Plasmalogen derivatives and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009371A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| US5731354A (en) | 1996-05-06 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Treatment for the inhibition of neuro-degenerative disease states |
| US6177476B1 (en) | 1998-08-27 | 2001-01-23 | Clarion Pharmaceuticals Inc. | Nutritional supplements for replenishing plasmalogens |
| CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
| JP2003530130A (ja) | 2000-04-14 | 2003-10-14 | メタボロン インコーポレイテッド | メタボロミクスを使用した薬物発見、疾患の処置、及び診断のための方法 |
| EP1317765A2 (de) | 2000-09-08 | 2003-06-11 | Oxford GlycoSciences (UK) Limited | Automatisierte peptiderkennung |
| DE10291524D2 (de) * | 2001-04-06 | 2004-07-01 | Anker Thorsten | Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien |
| EP1389306A2 (de) | 2001-05-09 | 2004-02-18 | BioVisioN AG | Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien |
| DE60333608D1 (de) | 2002-08-23 | 2010-09-09 | Bayer Schering Pharma Ag | Biomarker zur Diagnose von Alzheimer |
| EP2369348A1 (de) * | 2003-11-07 | 2011-09-28 | Ciphergen Biosystems, Inc. | Biomarker für Morbus Alzheimer |
| WO2005085838A2 (en) * | 2004-03-02 | 2005-09-15 | Vanderbilt University | Computational analysis of mass spectroscopic lipid data |
| WO2005116659A2 (en) | 2004-05-18 | 2005-12-08 | Neurodx, Llc | Compositions and methods relating to alzheimer’s disease |
| JP4176749B2 (ja) * | 2005-07-29 | 2008-11-05 | 学校法人帝京大学 | 疾病検査法 |
| US8026099B2 (en) * | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
-
2007
- 2007-02-28 EP EP10195818A patent/EP2322531A3/de not_active Ceased
- 2007-02-28 CA CA2640748A patent/CA2640748C/en active Active
- 2007-02-28 AU AU2007219666A patent/AU2007219666A1/en not_active Abandoned
- 2007-02-28 WO PCT/CA2007/000313 patent/WO2007098585A1/en not_active Ceased
- 2007-02-28 AT AT07710657T patent/ATE535535T1/de active
- 2007-02-28 US US12/280,920 patent/US8304246B2/en active Active
- 2007-02-28 KR KR1020087023687A patent/KR20080104350A/ko not_active Withdrawn
- 2007-02-28 EP EP14187832.2A patent/EP2851369A3/de not_active Withdrawn
- 2007-02-28 EP EP07710657A patent/EP1922325B1/de active Active
- 2007-02-28 CA CA2689848A patent/CA2689848A1/en not_active Abandoned
- 2007-02-28 NZ NZ570413A patent/NZ570413A/en unknown
- 2007-02-28 JP JP2008556622A patent/JP5496513B2/ja active Active
-
2008
- 2008-08-08 HK HK15109254.5A patent/HK1208467A1/en unknown
- 2008-08-13 IL IL193426A patent/IL193426A0/en unknown
-
2012
- 2012-07-31 JP JP2012169181A patent/JP2012255793A/ja active Pending
- 2012-09-25 US US13/626,703 patent/US20130110408A1/en not_active Abandoned
-
2014
- 2014-06-26 JP JP2014131876A patent/JP2014197018A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1208467A1 (en) | 2016-03-04 |
| EP1922325A1 (de) | 2008-05-21 |
| EP2322531A3 (de) | 2011-09-07 |
| CA2640748A1 (en) | 2007-09-07 |
| NZ570413A (en) | 2011-07-29 |
| EP1922325B1 (de) | 2011-11-30 |
| EP2322531A2 (de) | 2011-05-18 |
| IL193426A0 (en) | 2009-05-04 |
| US20130110408A1 (en) | 2013-05-02 |
| JP5496513B2 (ja) | 2014-05-21 |
| US8304246B2 (en) | 2012-11-06 |
| US20100003761A1 (en) | 2010-01-07 |
| EP2851369A3 (de) | 2015-06-17 |
| CA2689848A1 (en) | 2007-09-07 |
| JP2009528517A (ja) | 2009-08-06 |
| CA2640748C (en) | 2010-04-20 |
| EP1922325A4 (de) | 2009-05-27 |
| EP2851369A2 (de) | 2015-03-25 |
| WO2007098585A1 (en) | 2007-09-07 |
| AU2007219666A1 (en) | 2007-09-07 |
| KR20080104350A (ko) | 2008-12-02 |
| HK1113160A1 (en) | 2008-09-26 |
| JP2014197018A (ja) | 2014-10-16 |
| JP2012255793A (ja) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1922325A4 (de) | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen | |
| Edler et al. | Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease | |
| BRPI0516674A (pt) | método de análise de mal de alzheimer e reagente de diagnóstico | |
| DE60332538D1 (de) | Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen | |
| DE60016178D1 (de) | Verfahren zur diagnose und zur charakterisierung von schlaganfall | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| WO2005042761A3 (en) | Biomarkers for amyotrophic lateral sclerosis | |
| DE602006015281D1 (de) | Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind | |
| WO2007121009B1 (en) | Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy | |
| DE60326153D1 (de) | Verfahren zur diagnose von morbus alzheimer | |
| DK1953556T3 (da) | Polypeptidbiomarkører til diagnose af Alzheimer's sygdom | |
| SG171691A1 (en) | Biomarkers for diagnosing multiple sclerosis, and methods thereof | |
| EP2672266A3 (de) | Verfahren zum Screening einer Lungen-Transplantation Kandidat für ein erhöhtes Risiko einer Abstoßung | |
| WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
| DK1664793T3 (da) | Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser | |
| EP1600513A4 (de) | Verfahren zur untersuchung einer zelle | |
| ATE483982T1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
| EP2338988A4 (de) | Beurteilungs-/screeningverfahren für erkrankungen in zusammenhang mit d-aminosäure mittels dao1-/-maus | |
| Klunk et al. | Small molecule beta-amyloid probes which distinguish homogenates of Alzheimer's and control brains | |
| JP2009210469A (ja) | 血清たんぱく質の解析法 | |
| BR0209681A (pt) | Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente | |
| Singhal et al. | Salivary biomarkers for neurodegenerative disorder for biomedical sensing | |
| Klunk et al. | Quantitative in vitro NMR analysis of Alzheimer's, non-Alzheimer's demented and control brain | |
| ATA19972000A (de) | Pibf für die diagnose von tumoren | |
| ATE509270T1 (de) | Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung |